Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518920 · ClinicalTrials.gov registry record · Phase 1
A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01518920 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 44 participants.
The verdict
NCT01518920, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.
Interventions
- DRUG Placebo
- DRUG PF-04958242
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01518920
The ClinicalTrials.gov registry entry for NCT01518920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01518920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01518920 about?
NCT01518920 is a clinical study titled "A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss". The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.
What is the current status of trial NCT01518920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2011-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01518920?
The interventions under investigation include: Placebo (DRUG), PF-04958242 (DRUG).
Who is sponsoring clinical trial NCT01518920?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.